Abiopharma

🔍 Maddison John Anthony (Executive)

Company: F5, INC. (FFIV)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 454 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,379.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 230 shares of Common Stock at $323.2 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 3,149.00 | transaction_form_type: 4
• Sold 1,000 shares of Common Stock at $322.33 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,149.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 454 shares of Restricted Stock Unit (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,541.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5

Footnotes:

• F1: Shares acquired upon the vesting of the November 3, 2025 award of service-based Restricted Stock Units.
• F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan dated 11/06/2025.
• F3: Each Restricted Stock Unit represents a contingent right to receive one share of F5, Inc. Common Stock on the vest date.
• F4: This November 3, 2025 award of service-based Restricted Stock Units vests in twelve equal quarterly increments beginning February 1, 2026.
• F5: If the reporting person continues to provide services to the Company through the vest date, the corresponding number of shares of Common Stock of F5, Inc. will be issued to the reporting person on the vest date.